Feasibility study for proton dose calculation of esophageal squamous cell carcinoma based on stopping power ratio directly derived from dual energy CT

Miaomiao Li, Yongbin Cui, Xihuang Lin, Yuanyuan Yan, Qianyu Liu, Mingming Nie, Weijie Ye, Yong Huang, Jinhu Chen, Yong YinFrontiers in Oncology 2025 · DOI

TL;DR

This study evaluates whether direct stopping power ratio (SPR) maps from dual-energy CT (DECT) improve proton therapy planning for esophageal cancer compared to standard Hounsfield Unit (HU) conversion. The results show that while proton therapy significantly outperforms traditional photon-based radiation in sparing the heart and lungs, the standard CT-to-SPR conversion method remains remarkably robust and clinically comparable to the more advanced DECT-derived approach.

What Problem Does This Paper Address?

Proton therapy is prized for its "Bragg peak"—the ability to deposit the majority of its radiation dose at a specific depth, sparing healthy tissue behind the tumor. However, this precision is a double-edged sword: if the calculation of how protons slow down in tissue is slightly off, the dose can land in the wrong place.

This calculation relies on the Stopping Power Ratio (SPR). Traditionally, clinicians estimate SPR by taking a standard CT scan and using a "lookup table" to convert Hounsfield Units (HU) into SPR. This method is an approximation and can introduce "range uncertainties." Dual-Energy CT (DECT) offers a potential fix by using two different X-ray energy levels to more accurately characterize tissue composition, allowing for the direct generation of SPR maps. This paper investigates whether this high-tech direct mapping actually translates to better treatment plans for patients with esophageal squamous cell carcinoma (ESCC).

Methods

The researchers conducted a retrospective analysis of 30 patients with mid-thoracic ESCC. For each patient, they generated three distinct treatment plans:

  1. IMRT: Traditional photon-based intensity-modulated radiotherapy.
  2. IMPT (Standard): Intensity-modulated proton therapy using the traditional HU-to-SPR conversion.
  3. IMPT-SPR: Intensity-modulated proton therapy using direct SPR maps derived from a dual-layer spectral CT (Philips Spectral CT 7500).

The team compared these plans using several dosimetric metrics, including the Homogeneity Index (HI), Conformity Index (CI), and Gradient Index (GI), alongside specific dose-volume parameters for the heart, lungs, and spinal cord.

Datasets

The study utilized a clinical dataset of 30 patients with endoscopically confirmed ESCC treated at the Shandong Cancer Hospital and Institute between February and October 2024. The cohort included various stages (I-IV) and tumor locations, though the focus remained on mid-thoracic lesions to minimize variables like extreme respiratory motion or complex anatomy near the diaphragm.

Key Insights and Ideas

  • The "Good Enough" Standard: Perhaps the most surprising finding was that the traditional HU-to-SPR conversion performed nearly identically to the direct DECT-SPR mapping in terms of target coverage and organ-at-risk (OAR) protection. This suggests that for mid-thoracic esophageal cases, the current clinical standard is highly reliable.
  • Sharper Fall-off with Direct SPR: The only statistically significant difference between the two proton approaches was the Gradient Index (GI). The direct SPR plans showed a lower GI, indicating a slightly steeper dose fall-off at the edge of the target. This suggests that DECT might allow for even tighter margins in highly complex cases.
  • Protons vs. Photons is the Real Story: While the two proton methods were similar, both were vastly superior to IMRT. The ability of protons to spare the heart and lungs was dramatic, which is critical for esophageal patients who often face significant cardiac and pulmonary toxicity from radiation.

Key Results

  • OAR Sparing: IMPT plans (both types) showed significantly lower dose-volume parameters for the heart and lungs compared to IMRT. For example, the volume of the heart receiving 5 Gy (V5) was ~76.6% for IMRT but only ~22.3% for IMPT.
  • Direct SPR vs. HU-SPR: No significant differences were found in the mean dose ($D_{mean}$) or maximum dose ($D_{max}$) for the heart, lungs, or spinal cord between the two proton methods ($p > 0.05$).
  • Gradient Index: The GI was significantly higher (worse) in the HU-converted plans compared to the direct SPR plans ($p < 0.05$), suggesting direct SPR mapping provides a more "compact" dose distribution.

Limitations and Future Work

The authors acknowledge several limitations that pave the way for future research:

  • Sample Size and Location: The study was limited to 30 patients with mid-thoracic tumors. Results might differ for lower esophageal tumors where respiratory motion and tissue heterogeneity (near the stomach/diaphragm) are more pronounced.
  • Lack of "End-to-End" Validation: This was a planning study. The authors note the absence of experimental validation using physical phantoms to confirm that the calculated dose matches the delivered dose.
  • Motion Management: The study did not account for 4D-CT or respiratory gating, which are essential for managing uncertainties caused by breathing during treatment.

Future work should focus on larger, multi-institutional cohorts and incorporate 4D-DECT to see if direct SPR mapping offers a more distinct advantage when accounting for the moving anatomy of the chest.

Summary updated

Abstract

IMPT demonstrated superior OAR sparing compared to IMRT. For mid thoracic ESCC patients under proton therapy, dose calculations based on CT-HU conversion was showed comparable dosimetric impact to DECT-derived SPR in terms of target coverage and OAR protection. These findings support the clinical feasibility of conventional CT-based proton therapy planning and dose calculation.
BibTeX
@inproceedings{li2025feasibility,
  author = {Miaomiao Li and Yongbin Cui and Xihuang Lin and Yuanyuan Yan and Qianyu Liu and Mingming Nie and Weijie Ye and Yong Huang and Jinhu Chen and Yong Yin},
  title = {{Feasibility study for proton dose calculation of esophageal squamous cell carcinoma based on stopping power ratio directly derived from dual energy CT}},
  booktitle = {Frontiers in Oncology},
  year = {2025},
  doi = {10.3389/fonc.2025.1591139},
}
Figure